Latest Content

In phase 3 DREAM3R, first-line Imfinzi plus chemotherapy showed survival and response benefits in advanced mesothelioma, but results were inconclusive.

Adding Tecentriq to chemo resulted in survival outcomes comparable to placebo plus chemo in patients with advanced or recurrent endometrial cancer.

Trodelvy reduced risk of disease progression or death versus chemotherapy in patients with previously untreated metastatic triple-negative breast cancer.

Adding Truqap to Zytiga, prednisone, and ADT extended radiographic progression-free survival by 7.5 months in PTEN-deficient prostate cancer.

Consolidation tiragolumab plus Tecentriq does not improve progression-free survival in advanced lung cancer compared to Imfinzi.

Sac-TMT improved progression-free survival in patients with HR+/HER2– breast cancer.

Neoadjuvant Enhertu then THP improved pathological complete response rate in patients with high-risk, HER2-positive early breast cancer.

Postsurgical Libtayo and placebo showed similar rates of second primary tumors in high-risk CSCC

Enhertu led to a 53% reduction in the risk of invasive disease or death versus Kadcyla in some patients with high-risk, HER2-positive breast cancer.

Clinical trial results showed favorable results with Keytruda-based therapy in this ovarian cancer population.

Clinical trial data support the use of Imdelltra as a standard of care for all patients with second-line small cell lung cancer.

Lymphoma survivors with chronic fatigue participating in a multidisciplinary intervention program experienced benefits to fatigue and quality of life.

Among patients with solid tumors, baseline emotional functioning was moderate, with lower functioning for female and younger patients.